

24. The article of claim 21, wherein the article comprises from 0.0001% to 30%, by weight, of the protease inhibitor.

25. The article of claim 21 wherein an extract of at least a portion of the article produces at least a 10% reduction in substrate hydrolysis by a protease in an Absorbent Article Test Method.

26. An absorbent article, at least a portion of which comprises a protease inhibitor having an IC_{50} of 90 μ M or less, as measured by a Specific Fecal Protease Method.

27. The article of claim 26 wherein the IC_{50} is from 0.00001 μ M to 10 μ M.

28. The article of claim 26, wherein the protease inhibitor is selected from the group consisting of soybean trypsin inhibitor; lima bean protease inhibitor; corn protease inhibitor; Bowman Birk inhibitor; human pancreatic trypsin inhibitor; bovine pancreatic basic trypsin inhibitor; egg white trypsin inhibitor; egg white ovomucoids containing ovoinhibitors; chymostatin; aprotinin; leupeptin and its analogs; bestatin and its analogs; amastatin and its analogs; antipain; antithrombin III; hirudin; cystatin; E-64 and its analogs; α_2 -macroglobulin; α_1 -antitrypsin; pepstatin and its analogs; apstatin; (2R)-2-mercaptomethyl-4-methylpentanoyl-b-(2-naphthyl)-Ala-Ala amide; (2R)-2-mercaptomethyl-4-methylpentanoyl-Phe-Ala amide; N-acetyl-Leu-Leu-methioninal; N-acetyl-Leu-Leu-norleucinal; p-aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic acid; 2(R)-[N-(4-methoxyphenylsulfonyl)-N-(3-pyridylmethyl)amino]-3-methylbutano-hydroxamic acid; hexamidine and its salts; pentamidine and its salts; benzamidine and its salts and derivatives; p-aminobenzamidine and its salts and derivatives; guanidinobenzoic acid and its salts and derivatives; and mixtures thereof.

29. The article of claim 26 further comprising a delivery system for containing the protease inhibitor and delivering the inhibitor to at least a portion of the skin of a wearer of the article.

30. The article of claim 29, wherein the delivery system is a skin care composition wherein the skin care composition comprises from 0.01% to 50%, by weight, of the protease inhibitor, wherein at least a portion of the skin care composition is transferred from the article to a wearer's skin during wear of the article.

0044052560

Sub B1
31. An absorbent article, at least a portion of which comprises a protease inhibitor wherein the protease inhibitor has an IC_{50} of 500 μM or less, as measured by a General Fecal Protease Method.

32. The article of claim 31 wherein the IC_{50} is no more than 100 μM .

33. The article of claim 31 wherein an extract of at least a portion of the article produces at least a 10% reduction in substrate hydrolysis by a protease in an Absorbent Article Test Method.

34. The article of claim 31 wherein the protease inhibitor is 4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride.

35. The article of claim 31 further comprising a wearer-contacting surface, wherein at least a portion of the wearer-contacting surface comprises a skin care composition containing the protease inhibitor.

36. An absorbent article wherein an extract of at least a portion of the absorbent article produces a 20% reduction in substrate hydrolysis by a protease in an Absorbent Article Test Method.

37. An absorbent article containing a substance selected from the group consisting of soybean trypsin inhibitor; lima bean protease inhibitor; corn protease inhibitor; Bowman Birk inhibitor; human pancreatic trypsin inhibitor; bovine pancreatic basic trypsin inhibitor; egg white trypsin inhibitor; egg white ovomucoids containing ovoinhibitors; chymostatin; aprotinin; leupeptin and its analogs; bestatin and its analogs; amastatin and its analogs; antipain; antithrombin III; hirudin; cystatin; E-64 and its analogs; α_2 -macroglobulin; α_1 -antitrypsin; pepstatin and its analogs; apstatin; (2R)-2-mercaptomethyl-4-methylpentanoyl-b-(2-naphthyl)-Ala-Ala amide; (2R)-2-mercaptomethyl-4-methylpentanoyl-Phe-Ala amide; N-acetyl-Leu-Leu-methioninal; N-acetyl-Leu-Leu-norleucinal; p-aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic acid; 2(R)-[N-(4-methoxyphenylsulfonyl)-N-(3-pyridylmethyl)amino]-3-methyl-butano hydroxamic acid; 4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride; hexamidine and its salts; pentamidine and its salts; benzamidine and its salts and derivatives; p-aminobenzamidine and its salts and derivatives;

00448152562560

Sub C4